ALK and cancer: Moreover, in cancer-related nonhistone methylation, SMYD2 methylates the RB1, ALK, and β-catenin proteins to regulate the cell cycle and cell proliferation, implying that SMYD2 is a potential therapeutic target for cancer treatment17–20.